173 related articles for article (PubMed ID: 19474164)
1. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
Gridelli C; Rossi A; Maione P; Rossi E; Castaldo V; Sacco PC; Colantuoni G
Oncologist; 2009 Jun; 14(6):612-20. PubMed ID: 19474164
[TBL] [Abstract][Full Text] [Related]
2. Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer.
Baguley BC
Clin Lung Cancer; 2011 Mar; 12(2):81-6. PubMed ID: 21550553
[TBL] [Abstract][Full Text] [Related]
3. Current development status of small-molecule vascular disrupting agents.
Chaplin DJ; Horsman MR; Siemann DW
Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
[TBL] [Abstract][Full Text] [Related]
4. Clinical trials of vascular disrupting agents in advanced non--small-cell lung cancer.
McKeage MJ
Clin Lung Cancer; 2011 May; 12(3):143-7. PubMed ID: 21663855
[TBL] [Abstract][Full Text] [Related]
5. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.
McKeage MJ; Baguley BC
Cancer; 2010 Apr; 116(8):1859-71. PubMed ID: 20166210
[TBL] [Abstract][Full Text] [Related]
6. [New strategies for NSCLC: is inhibition of tumour vasculature useful].
Reinmuth N; Steins M; Kreuter M; Thomas M
Pneumologie; 2010 Jun; 64(6):376-86. PubMed ID: 20229453
[TBL] [Abstract][Full Text] [Related]
7. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
Head M; Jameson MB
Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
[TBL] [Abstract][Full Text] [Related]
8. Vascular disrupting agents.
Pilat MJ; Lorusso PM
J Cell Biochem; 2006 Nov; 99(4):1021-39. PubMed ID: 16927308
[TBL] [Abstract][Full Text] [Related]
9. Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy.
Bagley RG; Rouleau C; Morgenbesser SD; Weber W; Cook BP; Shankara S; Madden SL; Teicher BA
Microvasc Res; 2006 May; 71(3):163-74. PubMed ID: 16624341
[TBL] [Abstract][Full Text] [Related]
10. Vascular disrupting agents.
Lippert JW
Bioorg Med Chem; 2007 Jan; 15(2):605-15. PubMed ID: 17070061
[TBL] [Abstract][Full Text] [Related]
11. Vascular disrupting agents in clinical development.
Hinnen P; Eskens FA
Br J Cancer; 2007 Apr; 96(8):1159-65. PubMed ID: 17375046
[TBL] [Abstract][Full Text] [Related]
12. Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery.
Cooney MM; van Heeckeren W; Bhakta S; Ortiz J; Remick SC
Nat Clin Pract Oncol; 2006 Dec; 3(12):682-92. PubMed ID: 17139319
[TBL] [Abstract][Full Text] [Related]
13. Vascular-targeting therapies for treatment of malignant disease.
Siemann DW; Chaplin DJ; Horsman MR
Cancer; 2004 Jun; 100(12):2491-9. PubMed ID: 15197790
[TBL] [Abstract][Full Text] [Related]
14. Advances in preclinical small molecules for the treatment of NSCLC.
Zhang Q; Feng W; Zhou H; Yan B
Expert Opin Ther Pat; 2009 Jun; 19(6):731-51. PubMed ID: 19456275
[TBL] [Abstract][Full Text] [Related]
15. Disrupting tumour blood vessels.
Tozer GM; Kanthou C; Baguley BC
Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
[TBL] [Abstract][Full Text] [Related]
16. Vascular disrupting agents: a delicate balance between efficacy and side effects.
Hollebecque A; Massard C; Soria JC
Curr Opin Oncol; 2012 May; 24(3):305-15. PubMed ID: 22410458
[TBL] [Abstract][Full Text] [Related]
17. Multitargeted inhibitors in lung cancer: new clinical data.
Bar J; Herbst RS; Onn A
Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises.
Van Langendonckt A; Donnez J; Defrère S; Dunselman GA; Groothuis PG
Mol Hum Reprod; 2008 May; 14(5):259-68. PubMed ID: 18430758
[TBL] [Abstract][Full Text] [Related]
19. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer.
Ng QS; Goh V; Carnell D; Meer K; Padhani AR; Saunders MI; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1375-80. PubMed ID: 17275203
[TBL] [Abstract][Full Text] [Related]
20. Vascular damaging agents.
Patterson DM; Rustin GJ
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):443-56. PubMed ID: 17459681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]